Open access
Open access
Powered by Google Translator Translator

[Preprint] Pfizer vaccine less effective for SARS-CoV-2 variant B.1.351

12 Apr, 2021 | 01:26h | UTC

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals – medRxiv

Commentaries: South African variant may evade protection from Pfizer vaccine, Israeli study says – Reuters AND Israeli data shows South African variant able to ‘break through’ Pfizer vaccine – The Times of Israel

Related: Another study indicates SARS-CoV-2 variant B.1.351, but not variant B.1.1.7, has partial resistance to neutralizing antibodies generated by natural infection or mRNA vaccination AND SARS-CoV-2 variants B.1.351 and P.1 can escape from therapeutic antibodies and evade antibodies induced by infection or mRNA vaccination AND B.1.351 strain of SARS-CoV-2 neutralization titer reduced 8- to 9-fold for Pfizer and AstraZeneca vaccinees. Convalescent plasma and therapeutic antibodies were less effective against this variant as well.

 


Stay Updated in Your Specialty

No spam, just news.